Premium
Dipeptidyl peptidase‐ IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database
Author(s) -
García M.,
Aranburu M. A.,
PalaciosZabalza I.,
Lertxundi U.,
Aguirre C.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12397
Subject(s) - bullous pemphigoid , vildagliptin , medicine , pharmacovigilance , alogliptin , pemphigoid , metformin , dermatology , linagliptin , saxagliptin , dipeptidyl peptidase 4 , dipeptidyl peptidase 4 inhibitor , pharmacology , sitagliptin , diabetes mellitus , drug , endocrinology , immunology , type 2 diabetes mellitus , type 2 diabetes , antibody
Summary What is known and objective Bullous pemphigoid has been reported in association with gliptins. We describe a case, review the literature and analyse all cases of bullous pemphigoid recorded in the European pharmacovigilance database, EudraVigilance. Case summary A 74‐year‐old woman, treated with vildagliptin/metformin for 12 months, developed bullous pemphigoid, confirmed by skin biopsy. The symptoms resolved within 7 months after vildagliptin/metformin withdrawal. What is new and conclusion A search in EudraVigilance showed a disproportionality for bullous pemphigoid and gliptins, except alogliptin. These findings extend the evidence associating gliptins with this potentially serious disease.